By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Atossa Genetics today filed a preliminary prospectus with the US Securities and Exchange Commission to raise up to $17.6 million from an initial public offering.

Proceeds from the offering will be used to create a cytology and molecular diagnostics laboratory focused on breast cancer, and to manufacture and launch its FDA-cleared Mammary Aspirate Specimen Cytology Test System in the Northwestern US, the Seattle-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.